Company: GlaxoSmithKline plc

Prestige Brands Holdings Inc. said Thursday that it posted a $15,000 fiscal fourth-quarter loss on the costs of acquiring 17 healthcare brands from GlaxoSmithKline plc.

Human Genome Sciences said on Thursday it had adopted a stockholder rights plan as the biotechnology company defends itself against a $2.6 billion hostile takeover bid by drugmaker GlaxoSmithKline.

LONDON (Reuters) - Britain faces a worsening shortages of medicines because vital supplies are being sucked out of the country by exporters who can sell them for higher prices elsewhere, lawmakers said.

NEW YORK (Reuters) - GlaxoSmithKline will need to sweeten its $13 per share bid for Human Genome Sciences to about $15 per share to win over its top investors and get a deal done, according to a Reuters survey of analysts on Wednesday.

Stocks ended off their worst levels Wednesday following news that Greece will receive another bailout payment, but still closed in negative territory amid lingering concerns over the rest of the euro zone.

LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.

LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.

LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.

LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.

LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.

LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.

LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.

GlaxoSmithKline is to take its unsolicited $2.6 billion takeover bid for Human Genome Sciences direct to shareholders in the U.S. biotech group by launching a tender offer at $13 a share this week.

(Reuters) - Prosecutors in a number of states have charged dozens of suspects with stealing prescription drugs from warehouses and tractor trailers across the country, including two brothers accused of grabbing more than $70 million of prescription drugs two years ago from an Eli Lilly & Co warehouse in Connecticut.

(Reuters) - U.S. prosecutors in a number of states have charged dozens of suspects with stealing prescription drugs from warehouses and tractor trailers across the country, including two brothers accused of grabbing more than $70 million of prescription drugs two years ago from an Eli Lilly & Co warehouse in Connecticut.